biol gicas < biologic < biological

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by biologic

Number of relevant bibliographic references: 315.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000023 (2020)	Yehyun Park [Corée du Sud] ; Jae Hee Cheon [Corée du Sud]	Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
000047 (2020)	María Martín-L Pez [Espagne] ; Eliseo Albert [Espagne] ; Mario Fernández-Ruiz [Espagne] ; Isidoro González-Álvaro [Espagne] ; Esther Rodríguez [Espagne] ; José M. Aguado [Espagne] ; David Navarro [Espagne] ; José L. Pablos [Espagne]	Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies.
000118 (2020)	Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000151 (2020)	Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]	Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000197 (2020)	Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000204 (2020)	Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Lenore Tominna [États-Unis] ; Ibrahim Abbass [États-Unis]	Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
000205 (2020)	Karin Luttropp [Suède] ; Johan Dalén [Suède] ; Axel Svedbom [Suède] ; Mary Dozier [États-Unis] ; Christopher M. Black [États-Unis] ; Amy Puenpatom [États-Unis]	Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review
000216 (2020)	Elaheh Kordzadeh-Kermani [Iran] ; Hossein Khalili [Iran] ; Iman Karimzadeh [Iran] ; Mohammadreza Salehi [Iran]	Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators
000218 (2020)	Piero Ruscitti [Italie] ; Paola Cipriani [Italie] ; Vasiliki Liakouli [Italie] ; Daniela Iacono [Italie] ; Ilenia Pantano [Italie] ; Francesco Caso [Italie] ; Federico Perosa [Italie] ; Fabiola Atzeni [Italie] ; Francesco Paolo Cantatore [Italie] ; Raffaele Scarpa [Italie] ; Francesco Ciccia [Italie] ; Roberto Giacomelli [Italie]	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
000378 (2020)	Lianne Kearsley-Fleet [Royaume-Uni] ; Eleanor Heaf [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Eileen Baildam [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni] ; Helen E. Foster [Royaume-Uni] ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]	Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study
000385 (2020)	Gaëlle Vial [France] ; Anaïs De Pouilly [France] ; Laetitia Scouppe [France] ; Bruno Pereira [France] ; Claire Daien [France] ; Cédric Lukas [France] ; Adeline Ruyssen-Witrand [France] ; Pascale Vergne-Salle [France] ; Christophe Richez [France] ; Anne Tournadre [France]	Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score.
000439 (2020)	L. Baganz [Allemagne] ; J. Listing [Allemagne] ; J. Kekow [Allemagne] ; C. Eisterhues [Allemagne] ; S. Wassenberg [Allemagne] ; A. Zink [Allemagne] ; A. Strangfeld [Allemagne]	Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
000460 (2020)	Celine J. Van De Laar ; Martijn A H. Oude Voshaar ; Walid K H. Fakhouri [États-Unis] ; Liliana Zaremba-Pechmann [États-Unis] ; Francesco De Leonardis [États-Unis] ; Inmaculada De La Torre [États-Unis] ; Mart A F J. Van De Laar	Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
000473 (2020)	Konstantinos Thomas [Grèce] ; Emilia Hadziyannis [Grèce] ; Chrisoula Hatzara [Grèce] ; Anastasia Makris [Grèce] ; Christina Tsalapaki [Grèce] ; Argyro Lazarini [Grèce] ; Kalliopi Klavdianou [Grèce] ; Katerina Antonatou [Grèce] ; Christos Koutsianas [Grèce] ; Dimitrios Vassilopoulos [Grèce]	Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment
000486 (2020)	Rishi J. Desai ; Sara Dejene ; Yinzhu Jin ; Jun Liu ; Seoyoung C. Kim	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Drugs: A Cohort Study
000487 (2020)	Siddharth Singh ; Mathurin Fumery [France] ; Abha G. Singh ; Namrata Singh [États-Unis] ; Larry J. Prokop [États-Unis] ; Parambir S. Dulai ; William J. Sandborn ; Jeffrey R. Curtis	Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
000563 (2020)	Parth Shah ; Vinay Sundaram ; Einar Björnsson	Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review
000571 (2020)	Seong-Kyu Kim ; Sang Gyu Kwak [Corée du Sud] ; Jung-Yoon Choe	Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry.
000651 (2019)	Ben Mulhearn [Royaume-Uni] ; Anne Barton [Royaume-Uni] ; Sebastien Viatte [Royaume-Uni]	Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
000723 (2019)	Fenglong Xie [Royaume-Uni] ; Huifeng Yun [Royaume-Uni] ; Emily B. Levitan [Royaume-Uni] ; Paul Muntner [Royaume-Uni] ; Jeffrey R. Curtis [Royaume-Uni]	Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.
000743 (2019)	Amruta Trivedi [Australie] ; Constance Katelaris [Australie]	The use of biologic agents in the management of uveitis.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "biologic" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "biologic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    biologic
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021